SCHEMBL4841450

SCHEMBL4841450

N#Cc1ccccc1OCCC(=O)O

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.58
ALDH1A1 P00352 5/20 0.54
HPGD P15428 1/20 0.54
TSHR P16473 1/20 0.54
SMN1; SMN2 Q16637 3/20 0.52
GAA P10253 1/20 0.52
MAPK1 P28482 1/20 0.51
MMP2 P08253 1/20 0.50
NPC1 O15118 4/20 0.49
RAB9A P51151 4/20 0.49
TP53 P04637 2/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
FFAR1 O14842 3/20 0.48
KDM4E B2RXH2 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
FFAR4 Q5NUL3 1/20 0.46
NOTUM Q6P988 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3943926 0.92 ALDH1A1 (0.52) LMNAALDH1A1HPGDTSHRSMN1; SMN2
SCHEMBL3948176 0.90 ALDH1A1 (0.51) LMNAALDH1A1HPGDTSHRSMN1; SMN2
SCHEMBL3944392 0.89 ALDH1A1 (0.50) LMNAALDH1A1HPGDTSHRSMN1; SMN2
SCHEMBL3946276 0.89 ALDH1A1 (0.50) LMNAALDH1A1HPGDTSHRSMN1; SMN2
SCHEMBL2158544 0.89 ALDH1A1 (0.50) LMNAALDH1A1HPGDTSHRSMN1; SMN2
SCHEMBL31316798 0.85 ALDH1A1 (0.52) ALDH1A1HPGDTSHRSMN1; SMN2GAA
SCHEMBL7284807 0.85 LMNA (0.60) LMNAALDH1A1HPGDTSHRSMN1; SMN2
SCHEMBL1279945 0.83 SMN1; SMN2 (0.63) ALDH1A1HPGDTSHRSMN1; SMN2GAA
SCHEMBL4845134 0.83 ALDH1A1 (0.72) LMNAALDH1A1HPGDTSHRSMN1; SMN2
SCHEMBL12805341 0.79 ALDH1A1 (0.54) ALDH1A1HPGDTSHRSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743453-A1 MODULATORS OF MITOCHONDRIAL DNA REPLICATION Pretzel Therapeutics, Inc. (US) 2026-05-20 EP disclosed
WO-2025015178-A1 MODULATORS OF MITOCHONDRIAL DNA REPLICATION PRETZEL THERAPEUTICS, INC. (US) 2025-01-16 WO disclosed
US-7465811-B2 Indoline compounds LABORATOIRES FOURNIER S.A. (FR) 2008-12-16 US disclosed
US-20080119465-A1 Novel Indoline Compounds LABORATORIES FOURNIER S.A. (FR) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119465-A1 Novel Indoline Compounds GPR119, INSR, IRS1 LMNA 1943/4885ALDH1A1 1819/4885HPGD 3316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.